2016 record year for Amgen according consensus

Tomorrow the American Amgen will report her past quarter's results. Based on the analyst expectation both the revenue and the net profit would be on the highest levels in years. For this year the consensus of the revenue equals 22,77 billion dollars. The expectations would mean a record revenue for the company. This is slightly more than the 2015's revenue of 21,66 billion dollars.

Historical revenues and results Amgen plus taxations 2016

For 2016 the analysts foresee a record net profit of 8,59 billion dollars. For this year the analyst's consensus of Amgen 's result per share is a profit of 11,36 dollars. Based on this the price/earnings-ratio equals 13,9.

For this year the consensus of the dividend per share equals 3,91 dollars. The dividend yield consequently equals 2,48 percent. The average dividend of the biotech company equals 0,25 percent.

Most recent target prices around 187 dollars

The stock Amgen is being covered by 5 fundamental analysts. The average target price for the stock is at 182 dollars. This is around 14 percent more than the current stock price of 157,9 dollars. The three most recent recommendations for American were provided by BMO Capital Markets (buy, 190,00 dollars), Cowen and Company (buy, 209,00 dollars) and Sanford C. Bernstein & Co (hold, 161,00 dollars).

Based on the number of outstanding shares Amgen 's market capitalization equals 118,63 billion dollars.

The stock closed last Tuesday at 157,9 dollars.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.